AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01158443 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy
Description: 8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
Study NCT01158443 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Counseling
Description: 8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
Study NCT03970824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P17
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
Study NCT01853462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF training
Description: Ten individual PNF sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
Study NCT01853462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Ten individual balance sessions, supervised by a physical therapist, with 50-60 min duration per session, within a maximal five-week period
Study NCT01464645 — intervention group
Intervention type: DEVICE
Intervention: Modular Revision Hip System
Description: Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
Study NCT01050751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Oral Lersivirine 750 mg (1 x 750 mg) single dose
Study NCT01050751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: Oral Lersivirine 750 mg (3 x 250 mg) single dose
Study NCT01791491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Single intravenous infusion of belatacept, 7.5 mg/kg
Study NCT02325024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Study NCT01533766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SmofKabiven
Description: intravenously over 5 days infusion
Study NCT03552094 — intervention group
Intervention type: OTHER
Intervention: Blood donations of hemochromatosis or polycythemia patients
Description: Blood samples are from blood donations of hemochromatosis or polycythemia patients requiring therapeutic bleeding that are not used in medical applications.
Study NCT03204877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Oral capsules
Study NCT03204877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules
Study NCT01442337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8597
Description: one time IV dose
Study NCT01442337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one time IV dose
Study NCT03943290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein
Study NCT03571360 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PD-L1 positive vs PD-L1 negative NSCLC patients
Description: Genomic analyses of PD-L1 positive vs PD-L1 negative NSCLC patients
Study NCT04430361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol
Description: 160 mg of megestrol acetate dispersible tablets were taken orally every morning on the day of the beginning of chemotherapy for 10 days.
Study NCT03970824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-licensed Humira
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
Study NCT03970824 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-approved Humira
Description: 40 mg/0.4ml (100 mg/mL) administered as a single SC injection via PFS
Study NCT02593968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Interferon a-2b Gel
Study NCT02593968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04430361 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5-HT3 receptor antagonist
Description: 5-HT3 receptor antagonist 2.5mg/iv
Study NCT04430361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonist
Description: 5-HT3 receptor antagonist 2.5mg/iv
Study NCT04430361 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
Study NCT04430361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone 12mg on the first day, 8mg on the 2nd-4th day,
Study NCT00933439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
Study NCT01783197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT04749576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: saffron supplement for IBD
Description: anti inflammatory effect
Study NCT04749576 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: saffron supplement for IBD
Description: anti inflammatory effect
Study NCT01812122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Study NCT01783197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT01783197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Study NCT01783197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Study NCT01783197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT03552094 — intervention group
Intervention type: OTHER
Intervention: Blood donations of healthy donors
Description: Blood samples are from blood donations of healthy donors.
Study NCT01339663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01853891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dim light at night
Study NCT01812122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Study NCT02423460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Threonine
Description: Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
Study NCT03701204 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DynamiCare Rewards
Description: Participants assigned to the DynamiCare Rewards group will receive the following:~1. App on their smartphone~2. Substance Testing Devices: BACTrack Mobile Pro - submits BAC results directly to smartphone via Bluetooth and Saliva Test Kits.~3. Next Step debit card to receive financial incentives~4. Participant will be prompted via the app to conduct breathalyzer/saliva tests, using the devices camera to take selfie photo/videos to prevent cheating.~5. Negative tests result in participant receiving electronic virtual coins, which can be transferred from reserve account (reserve account inaccessible to participant) to the spendable Next Step debit card.~6. The amount of coins and funds are available on a progressive variable reward schedule.
Study NCT01162304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended Release Oxycodone
Description: 40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
Study NCT01162304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Release Oxycodone
Description: IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
Study NCT03994276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
Study NCT03994276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
Study NCT03994276 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chickpea powder
Description: Chickpea powder is produce using novel production techniques to maintain chickpea cell structure. It will be incorporated into a drink (Dextrose control), or baked into bread rolls at 30% or 60% substitution of wheat flour(100% Wheat flour control).
Study NCT01339663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT01339663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: Receive T-APC via IV
Study NCT01339663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01339663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies
Study NCT01339663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01339663 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative studies
Study NCT01339663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
Study NCT00512382 — intervention group
Intervention type: DEVICE
Intervention: WEEM - Wheezy Monitoring
Description: loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
Study NCT03805100 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Intravitreal injection
Study NCT03805100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection
Study NCT02307266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care + supplementary education
Study NCT02307266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care + additional visits
Study NCT02307266 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of care
Study NCT02291770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stromal Cells
Description: Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
Study NCT03233230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2591 25 mg QD
Description: Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.
Study NCT03233230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 75 mg QD
Description: Participants received 75 mg of M2951 orally QD for 12 weeks.
Study NCT03233230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2951 50 mg BID
Description: Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.
Study NCT03233230 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M2951 orally for 12 weeks.
Study NCT01179698 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Navigation surgery
Description: In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
Study NCT01179698 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Navigation system
Description: In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
Study NCT00658645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifeprunox
Description: 20 mg daily, encapsulated tablets, orally, 12 months
Study NCT00658645 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Encapsulated tablets, orally, 12 weeks
Study NCT00658645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: 600 mg daily, encapsulated tablets, orally, 12 months
Study NCT02454660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS (Text messages)
Description: Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
Study NCT00167687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prazosin
Description: Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:~Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg
Study NCT03063840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
Study NCT04921020 — intervention group
Intervention type: OTHER
Intervention: Photography
Description: Facial photographs and blinking videos are taken
Study NCT00010192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00010192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given SC
Study NCT00010192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00010192 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT04607330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein liquid
Description: After a 1-day baseline period to establish patients' acceptability, gastrointestinal tolerance, compliance, dietary intake while also capturing information related to user experience, risk of malnutrition, physical function, dietary intake, anthropometry and safety with their currently prescribed nutritional regimen, each patient will receive the high protein liquid daily for 28 days where the same measures will be replicated. The amount of the high protein liquid prescribed will always be completed by the patients' managing dietitian.
Study NCT01299259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message Reminders
Description: Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
Study NCT04544501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Targeted Video
Description: Culturally targeted narrative video: Is My Cancer Hereditary? Rosa Visits a Genetic Counselor. With R03 funding (R03CA191543) we developed a culturally targeted narrative video for at-risk Latinas. A multidisciplinary team of researchers collaborated with filmmakers to develop the script and video. The script was informed by health behavior conceptual models, evidence-based risk communication strategies, and formative research (40 interviews with providers and at-risk Latinas). The script addressed identified knowledge gaps (e.g., incorrect belief that pap smears screen for ovarian cancer), facilitators (e.g., inform family cancer risk), barriers (e.g., emotional concerns), and cultural factors (e.g., respect). The 18-minute video illustrates the GCRA process with the story of Rosa, a Latina cancer survivor at increased risk of HBOC. Rosa learns about HBOC risk factors, overcomes barriers, and attends genetic counseling.
Study NCT04544501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FORCE Fact Sheet
Description: A publically available Spanish-language fact sheet about HBOC and GCRA developed by FORCE.
Study NCT04492020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Description: For each qualifying prodrome event, 2 compressed tablets containing 50 mg of ubrogepant will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Study NCT04492020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For each qualifying prodrome event, 2 compressed tablets containing placebo will be taken orally when the participant is confident that a headache will follow within 1-6 hours
Study NCT05084703 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Functional tests
Description: * Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test
Study NCT05084703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional tests
Description: * Symmetry indices between the two limbs obtained thanks to the scores of the functional tests : Y balance test~* Muscle endurance index obtained from functional test scores : Closed Kinetic Chain Upper Extremitie Stability test
Study NCT02438852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT02438852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02438852 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02438852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Hydrochloride
Description: Given IV
Study NCT00759135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5 mg NX-1207
Description: Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
Study NCT00759135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.125 mg NX-1207
Description: Low dose; single intraprostatic injection of 0.125 mg NX-1207
Study NCT00759135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: finasteride
Description: Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
Study NCT00859807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flavoquine®, Camoquin® Suspension
Description: Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
Study NCT00403013 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning and anesthesia
Description: Positioning during axillary plexus block
Study NCT00993304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
Study NCT00403013 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positioning and anesthesia
Description: Positioning during axillary plexus block
Study NCT04621994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermabond
Description: Dermabond will be applied after subcuticular skin closure in lieu of Steri Strips
Study NCT04621994 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Steri Strips
Description: Steri Strips will be applied after subcuticular skin closure as routinely done at our institution
Study NCT00628498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.~Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days.
Study NCT00628498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide